Case Report: Early recognition of neonatal alpha-1 antitrypsin deficiency: a case of subtle presentation and prompt diagnosis
-
By
-
Vinson James
-
Sydney Darling
-
Catherine Chin
-
Pomalpreet Bajwa
-
Adarsh Pillay
-
Jaime Chu
-
Yoseph Gurevich
-
Vindhya Kamath
-
June 24, 2026
-
Clinical Scorecard: Case Study: Timely Identification of Neonatal Alpha-1 Antitrypsin Deficiency in a Subtly Presenting Infant
At a Glance
| Category | Detail |
|---|
| Condition | Neonatal Alpha-1 Antitrypsin Deficiency |
| Key Mechanisms | Genetic deficiency leading to cholestasis and conjugated hyperbilirubinemia. |
| Target Population | Neonates, particularly those presenting with persistent conjugated hyperbilirubinemia. |
| Care Setting | Neonatal intensive care or pediatric gastroenterology. |
Key Highlights
- Diagnosis of A1AT deficiency confirmed by day 8 of life.
- Persistent conjugated hyperbilirubinemia prompted metabolic evaluation.
- A1AT deficiency is not included in routine newborn screening panels.
- Elevated GGT with normal ALT is a characteristic pattern in A1AT deficiency.
- Clinical improvement observed with supportive management.
Guideline-Based Recommendations
Diagnosis
- Consider metabolic and genetic disorders in neonates with conjugated hyperbilirubinemia after excluding infectious causes.
Management
- Supportive management including phototherapy for hyperbilirubinemia.
Monitoring & Follow-up
- Close follow-up with pediatric gastroenterology for ongoing management.
Risks
- Risks associated with liver biopsy in neonates with borderline coagulation parameters.
Patient & Prescribing Data
Infants diagnosed with A1AT deficiency.
Supportive care and monitoring are critical; specific treatment options may vary based on clinical presentation.
Clinical Best Practices
- Prioritize A1AT testing in cases of unexplained conjugated hyperbilirubinemia.
- Avoid invasive procedures unless absolutely necessary in neonates.
Related Resources & Content
